Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04369287 | Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia(Euro_IDH_AML) | unknown | — | 654 | Istituto Clinico HumanitasOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT03417427 | A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML | unknown | Phase 2 | 100 | Xuejie JiangOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT03600558 | Efficacy of FLAG Regimen for the Treatment of Patients With AML | unknown | — | 60 | Tianjin Medical University General HospitalOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04351022 | CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03547258 | Italian Non-Interventional Study of FLT3 Mutated AML Patients(FLAM) | unknown | — | 800 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT04070807 | Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2(AVALON) | unknown | — | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT04353479 | Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 29 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Apr 20, 2020 | clinicaltrials |
| NCT02856464 | Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy(PRO-DLI) | unknown | Phase 2 | 124 | King's College Hospital NHS TrustOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT02638428 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | unknown | Phase 2 | 90 | Samsung Medical CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04312607 | Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm | unknown | — | 80 | Safaa AA KhaledOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT04311060 | Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. | unknown | — | 100 | Mexican Agrupation for Hematology StudyOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02667093 | Samples From Leukemia Patients and Their Donors to Identify Specific Antigens | unknown | — | 50 | PersImmune, IncINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03755856 | Long-term Outcomes for Acute Myeloid Leukemia Patients(1621-QLG-LG) | unknown | — | 343 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 8 | Mar 4, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02059720 | Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 | unknown | Phase 3 | 212 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02156297 | Sorafenib to Treat FLT3-ITD AML | unknown | — | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations(AML18) | unknown | Phase 2 / Phase 3 | 1,600 | Cardiff UniversityOTHER | 2 | Jan 23, 2020 | clinicaltrials |
| NCT00525746 | Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) | unknown | — | 191 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02605460 | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | unknown | Phase 2 | 20 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04215822 | PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia | unknown | — | 80 | Assiut UniversityOTHER | 0 | Jan 3, 2020 | clinicaltrials |
| NCT04216771 | Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | unknown | Phase 2 / Phase 3 | 320 | Fujian Medical UniversityOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT02268370 | Treatment-free Remission Accomplished With Dasatinib in Patients With CML(TRAD) | unknown | Phase 2 | 131 | University Health Network, TorontoOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT03260101 | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | unknown | — | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT04168138 | D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients | unknown | N/A | 20 | Huihan WangOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04150471 | Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients | unknown | — | 79 | Seoul St. Mary's HospitalOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT03907670 | Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor | unknown | — | 45 | Assiut UniversityOTHER | 0 | Sep 30, 2019 | clinicaltrials |
| NCT04104035 | Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response | unknown | — | 100 | Ankara UniversityOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT04087967 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | unknown | Phase 3 | 162 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT04083911 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | unknown | Phase 3 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03181815 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01987297 | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | unknown | Phase 4 | 738 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT04060485 | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | unknown | — | 1,000 | National Taiwan University HospitalOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04043676 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 40 | Fundación Teófilo Hernando, SpainOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT03062436 | To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission | unknown | N/A | 27 | Command Hospital, IndiaOTHER_GOV | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04024241 | Medium Dose of Cytarabine and Mitoxantrone(HAM) | unknown | — | 250 | Shenzhen People's HospitalOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03337568 | Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission(AML_AlloHCT) | unknown | — | 110 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03885076 | Gamma Delta T Cells in AML | unknown | — | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT03978364 | A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC | unknown | Phase 3 | 100 | Shandong Provincial HospitalOTHER_GOV | 1 | Jun 7, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2020source: clinicaltrials